Received Jul 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Nausea; Gagging; Diarrhea; Fatigue; This non-serious case was reported by a consumer via call center representative and described the occurrence of nausea in a 74-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 27-MAR-2025, the patient received the 1st dose of Shingrix. On 28-MAR-2025, 1 days after receiving Shingrix, the patient experienced nausea (Verbatim: Nausea), gagging (Verbatim: Gagging), diarrhea (Verbatim: Diarrhea) and fatigue (Verbatim: Fatigue). The outcome of the nausea, gagging, diarrhea and fatigue were resolved. It was unknown if the reporter considered the nausea, gagging, diarrhea and fatigue to be related to Shingrix. It was unknown if the company considered the nausea, gagging, diarrhea and fatigue to be related to Shingrix. Additional Information: GSK Receipt Date: 27-JUN-2025 This report was submitted via the online direct entry reporting system. Reporter was the patient, who received her first dose of SHINGRIX on March 27. She stated that a day later, she experienced nausea, gagging, diarrhea, and fatigue. Symptoms resolved for a day and a half.